We live in an age of wide-reaching population health problems, such as diabetes, cardiovascular disease, and obesity, that have a huge physical, mental, and financial cost for patients and providers. However, new forms of artificial intelligence (AI) could be the answer to solving these population health problems in an efficient…

The National Institutes of Health (NIH) announced Thursday it will award $170 million to a variety of clinics and healthcare centers across the U.S. to help it establish the Nutrition for Precision Health (NPH) program. The new program, a part of the All of US Research Program, will seek to…

A novel immunotherapy strategy that generates transient engineered chimeric antigen receptor (CAR) T-cells in the body can reduce scarring and restore cardiac function in a mouse model of heart failure, according to research led by the University of Pennsylvania. The experimental immunotherapy approach is based on the delivery of modified…

Digital biology drug discovery company Recursion has secured a commitment of up to $12 billion from Roche and its Genetech subsidiary to apply its Recursion Operating Systemt (OS) to advance therapies across 40 program that include neuroscience and an undisclosed oncology indication the companies announced today. Recursion OS applies machine…

Cell culture studies by researchers at the University of Liverpool and Institut Pasteur in Paris suggest COVID-19 can be targeted using existing drugs. The new findings, published in Nature Communications, examine proteolysis during viral infection, and may help pinpoint targeted treatments against the virus. SARS-CoV-2 has been responsible for more than 227 million…

New evidence suggests ganciclovir may alter stem cell transplant patients’ DNA, but that transplanted stem cells do not. That’s according to a study by Researchers in the Van Boxtel group at the Princess Máxima Center for pediatric oncology. The researchers analyzed the DNA of blood cells in nine patients who…

A humanized mouse model that mimics a patient’s immune system is better than current approaches for identifying an optimal living organ donor, according to scientists at the Medical College of Georgia (MCG) in Augusta, USA. They call their approach an “immunobiological algorithm” that provides a comprehensive prospective on how a…

Originally named the Gene Security Network, clinical molecular testing company Natera was founded in 2004 by Jonathan Sheena and Matthew Rabinowitz. Both of the co-founders came from outside the life sciences industry: Sheena from mobile search engine technology company PhoneSpots, which pioneered the ‘send to mobile’ feature, and Rabinowitz at…

A genetically engineered strain of Bacteroides bacteria, designed to treat the kidney disease enteric hyperoxaluria, has gone into clinical trials. Developed by the San Francisco-based biotech Novome Biotechnologies, the engineered bacteria treatment, combined with a botanically derived polysaccharide, is designed to colonize the gut and degrade excessive amounts of oxalate…

BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), according to a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center.  BK virus-associated hemorrhagic cystitis is a painful complication and common after…

Researchers from Mount Sinai have shown that genetic ancestry can be used to better understand and predict who is more susceptible to certain disorders—including cancers, asthma, diabetes, and cardiovascular disease. They point out that this information could be used to develop early interventions. Their study was reported in the journal Cell.…

It is with great pleasure that we introduce to you our 2021 selections of Pioneers Under 40—scientists and businesspeople under the age of 40 who are making significant contributions in advancing precision medicine. While there are undoubtedly scores of other researchers and scientists not on this list that could qualify,…

Twenty years after the publication of the first draft of the human genome, our views have changed on the cipher for humanity, the identity of our ancestors, the differences among us, and the genomic nuances that can govern disease. Much has been deciphered and plenty remains. It is an opportune…

Last week, the National Institute of Allergy and Infectious Diseases (NIAID) announced the commencement of the Phase III trial (NCT04611802) of the Novavax investigational COVID-19 vaccine. The trial will evaluate the effectiveness, immune response, and safety of a COVID-19 vaccine candidate called NVX-CoV2373, and is estimated to complete data collection…

A Phase II/III trials of a two-antibody “cocktail” from Regeneron Pharmaceuticals, REGN-COV2, has met its primary endpoint of significantly reducing viral load and medical visits in ambulatory adults with COVID-19. However, the company is reviewing a possible change of dosages in the study after finding no significant difference in efficacy…